Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials

被引：1

作者：

Wei, Xiaoling ^{[1
]}

Passera, Anna ^{[2
]}

Muscianisi, Elisa

Uhlmann, Lorenz ^{[2
]}

Chen, Li ^{[3
]}

Moreno, Santiago G. ^{[2
]}

Martin, Ruvie ^{[3
]}

Vandemeulebroecke, Marc ^{[2
]}

Keefe, Deborah ^{[3
]}

Ravichandran, Shoba

Wozniak, Magdalena B. ^{[4
]}

机构：

[1] Novartis Pharm Shanghai, Shanghai, Peoples R China

[2] Novartis Pharm AG, Basel, Switzerland

[3] Novartis Pharmaceut, E Hanover, NJ USA

[4] Novartis Ireland Ltd, Dublin, Ireland

来源：

关键词：

acne inversa; hidradenitis suppurativa; HS-related pain; NRS30; pain measurement; secukinumab; validation;

D O I：

10.1016/j.jaad.2023.07.1035

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

[No abstract available]

引用

页码：1285 / 1287

页数：3